| Symbol | ANRO |
|---|---|
| Name | ALTO NEUROSCIENCE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, California, 94041, United States |
| Telephone | +1 650 200-0412 |
| Fax | — |
| — | |
| Website | https://www.altoneuroscience.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001999480 |
| Description | Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Alto Neuroscience, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0000935836-26-000361 <b>Size:</b> 15 KB
Read moreAlto Neuroscience, Inc. - Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Read moreAlto Neuroscience, Inc. - Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Read moreAlto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Read moreDirector Miller Andrew Craig 🟢 acquired 26.0K shares (1 derivative) of Alto Neuroscience, Inc. (ANRO) at $20.44 Transaction Date: May 27, 2026 | Filing ID: 000016
Read moreNew Form 3 - Alto Neuroscience, Inc. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001777760-26-000015 <b>Size:</b> 11 KB
Read more(99% Neutral) ALTO NEUROSCIENCE, INC. (ANRO) Announces New Board Appointment
Read moreAlto Neuroscience, Inc. - Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Read moreAlto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Read moreDirector Etkin Amit 🔴 sold 400.0K shares of Alto Neuroscience, Inc. (ANRO) Transaction Date: May 14, 2026 | Filing ID: 000006
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Apollo Armband | DEVICE | Approved | Fatigue | COMPLETED | NCT04983342 |
| Apollo Wearable | DEVICE | Approved | Stress Disorders, Post-Traumatic | RECRUITING | NCT05274230 |